ProQR Therapeutics N.V. (PRQR)
Nasdaq: PRQR · Pharmaceutical Preparations · Leiden, NL · filing with the SEC since 2014
Who owns ProQR Therapeutics N.V.
As filed with the SECHolders of 5% or more
5
Eli Lilly & Co. holds 15.6% of Ordinary Shares, nominal value 0.04 EUR per share, as its SCHEDULE 13G/A filed Jul 24, 2026 says.
Directors and officers
11
report now, of 11 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Eli Lilly & Co.
SCHEDULE 13G/A · filed Jul 24, 2026 · Ordinary Shares, nominal value 0.04 EUR per share
Van Herk Investments B.V.
SCHEDULE 13D/A · filed Jul 29, 2026 · Ordinary Shares, nominal value Euro 0.04 per share · 10.9% in Jun 30, 2026
Aberdeen Group plc
SCHEDULE 13G · filed Jul 29, 2026 · Ordinary Shares, nominal value EUR0.04 per share
Adage Capital Management, L.P.
SCHEDULE 13G/A · filed Aug 12, 2025 · Ordinary Shares, nominal value 0.04 euro per share · 7.7% in May 12, 2025
Patrick Johan Hendrik Krol
SCHEDULE 13G/A · filed Jul 15, 2026 · Ordinary Shares, nominal value EUR0.04 per share · 5.2% in Jan 20, 2026
What PRQR reports owning in othersstakes of 5% or more, and other ties
11 subsidiaries in 2 countries, from the list filed with the 20-F filed Mar 12, 2026.
Insider tradesForm 4
0sales
5purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$1.3Mbought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 11 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| De Boer Daniel Anton | Chief Executive Officer | 0 | $0 | 0 | 3 | $900,000 |
| Filius Bart | director | 0 | $0 | 0 | 2 | $500,000 |